Clinical Report: Molecular Subtyping and Immunotherapy in Endometrial Cancer
Overview
Endometrial cancer (EC) is increasingly prevalent, particularly among young women, necessitating fertility-sparing treatment (FST) options. Molecular subtyping reveals significant prognostic differences, with POLE mutations associated with better outcomes, while dMMR indicates poorer prognosis and higher recurrence rates.
Background
Endometrial cancer is one of the most common malignancies affecting women, with rising incidence rates linked to factors like obesity and delayed childbearing. Standard treatment typically involves hysterectomy, which eliminates fertility, prompting the need for fertility-sparing strategies. Recent advancements in molecular classification have provided insights into the varying prognoses associated with different subtypes of endometrial cancer.
Data Highlights
No numerical data available in the source material.
Key Findings
Endometrial cancer incidence was approximately 417,000 new cases globally in 2020.
POLE mutations are associated with a higher complete remission rate in fertility-sparing treatment.
Patients with dMMR endometrial cancer have a higher recurrence rate post-complete remission.
Traditional fertility-sparing regimens primarily utilize progestin therapy.
Clinical Implications
Clinicians should consider molecular subtyping when evaluating treatment options for young women with endometrial cancer seeking to preserve fertility.
Conclusion
Molecular classification plays a crucial role in guiding fertility-sparing treatment strategies for endometrial cancer.
